 |
Vol.62 No.4 contents | Japanese/English |
 | Full Text of PDF (556K) Article in Japanese |
- Original Article -
A Study of the Relationship Between Interstitial Lung Abnormalities and Osimertinib-induced Lung Injury
Masahiko Sumii1,2, Yusuke Takayama1, Shinji Kakumoto1, Shohei Mishima1, Ken Masuda1, Hiroyasu Shoda11Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital, Japan, 2Department of Respiratory Medicine, Hiroshima University Hospital, Japan
Background/Objective. While osimertinib is recommended as the first-line treatment of EGFR mutation-positive non-small cell lung cancer, it is known that drug-induced lung injury occurs frequently in patients receiving osimertinib. In addition, the presence of interstitial lung abnormalities (ILAs) is also known to be a risk factor for drug-induced lung injury. Therefore, we investigated whether or not ILAs were a risk factor for drug-induced lung injury caused by osimertinib based on the clinical experience at our hospital. Study Design. We retrospectively reviewed 106 patients with advanced-stage non-small cell lung cancer treated with osimertinib at our hospital from September 2018 to September 2020. Results. A multivariate logistic regression analysis showed that the presence of ILAs prior to treatment with osimertinib was a significant risk factor for drug-induced lung injury (odds ratio: 4.93, p<0.05). In addition, patients with a subpleural fibrotic pattern tended to have more severe drug-induced lung injury than others. Conclusion. ILAs may be a risk factor for drug-induced lung injury with osimertinib. In particular, patients with subpleural fibrotic pattern are at an increased risk of severe lung injury and thus should be carefully observed.
key words: Osimertinib, Non-small cell lung cancer, Drug-induced lung injury, Interstitial lung abnormalities (ILA)
Received: March 22, 2022
Accepted: April 25, 2022
JJLC 62 (4): 292-298, 2022
